A securities class action has been filed in the USDC –N.J. against Merck & Co., Inc. (MRK) (“Merck” or the “Company”) on behalf of all persons or entities who purchased or otherwise acquired Merck common stock between February 2, 2022, and February 3, 2025, both dates inclusive (the “Class Period”).
Merck is a global healthcare company that operates through two segments, Pharmaceutical and Animal Health, with a significant focus on prescription medications. In the Pharmaceutical segment, Merck sells both therapeutic and preventative agents, generally by prescription, to physicians, wholesalers, distributors, and government entities for appropriate treatment and distribution to patients.
The Complaint alleges that Defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Gardasil’s demand in China; notably, that Merck lacked visibility into demand for Gardasil in China among eligible and otherwise targeted populations, resulting in the inflated inventory of its distributor, Zhifei. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Merck’s securities at artificially inflated prices.
If you purchased Merck common stock during the class period, and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.